Rapid Micro Biosystems RPID Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Charles River LaboratoriesCRL

——

Pacific Biosciences of CaliforniaPACB

——

iRadimedIRMD

——

Ginkgo BioworksDNA

——

FuelCell EnergyFCEL

——

Other financials

Income statement

See full

Revenue$8.0M+11.1%

Gross profit$371.0K-8.2%

Operating income-$13.9M-18.8%

Net income-$14.3M-26.7%

EPS (diluted)-$0.31-19.2%

Balance sheet

See full

Cash & equivalents$14.1M-26.8%

Total debt$23.8M+301%

Total equity$20.4M-68.9%

Total assets$62.4M-27.0%

Cash flow

See full

Operating cash flow-$15.1M-66.1%

CapEx$394.0K+23.5%

Free cash flow-$15.5M-64.7%

Valuation

See full

Market cap$86.19M-43.8%

Enterprise value$95.86M-31.7%

P/S2.5×-2.6×

Profitability

See full

Operating margin-144.2%-12.7pp

Net margin-145.8%-5.0pp

FCF margin-110.5%-14.9pp

Returns & leverage

See full

Return on equity-116.7%-620pp

Debt / equity1.2×+1.1×

Current ratio2.6×-2.0×

Where this comes from

Reported directly by Rapid Micro Biosystems in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapid Micro Biosystems's deferred revenue, net of current portion?: Rapid Micro Biosystems (RPID) reported deferred revenue, net of current portion of $0 in Q1 2026.